$CDAQF
Compass Digital Acquisition Corp. Stock $cdaqf

$cdaqf Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000149315224012485 Filed on April 01, 2024

Income Statement

Concept	2023 Q4	2023	2022 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$50.00K	$120.0K
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$4.244M	$5.491M	$570.2K
YoY Change	644.18%	356.04%	-45.82%
Operating Profit		-$5.491M
YoY Change		356.04%
Interest Expense	$1.185M	$8.914M	$1.834M
YoY Change	-35.39%	186.3%	56500.0%
% of Operating Profit
Other Income/Expense, Net	$2.035M	$611.3K	$119.1K
YoY Change	1608.03%	-94.18%	-131.69%
Pretax Income	-$1.024M	$4.386M	$1.383M
YoY Change	-174.07%	-52.81%	-197.03%
Income Tax
% Of Pretax Income
Net Earnings	-$1.024M	$4.386M	$1.383M
YoY Change	-174.07%	-52.81%	-197.03%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.08	$0.19	$0.05
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q4	2023	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$44.05K	$44.05K	$936.4K
YoY Change	-95.3%	-95.3%	-47.63%
Cash & Equivalents	$44.05K		$936.4K
Short-Term Investments
Other Short-Term Assets	$35.64K	$35.64K	$341.0K
YoY Change	-89.55%	-89.55%	-18.85%
Inventory
Prepaid Expenses	$35.64K		$341.0K
Receivables
Other Receivables
Total Short-Term Assets	$79.68K	$79.68K	$1.277M
YoY Change	-93.76%	-93.76%	-42.15%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$55.35M	$55.35M	$215.5M
YoY Change	-74.32%	-74.32%	1.47%
Other Assets			$0.00
YoY Change			-100.0%
Total Long-Term Assets	$55.35M	$55.35M	$215.5M
YoY Change	-74.32%	-74.32%	1.31%
TOTAL ASSETS
Total Short-Term Assets	$79.68K	$79.68K	$1.277M
Total Long-Term Assets	$55.35M	$55.35M	$215.5M
Total Assets	$55.43M	$55.43M	$216.8M
YoY Change	-74.43%	-74.43%	0.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$476.6K	$476.6K	$953.5K
YoY Change	-50.02%	-50.02%
Accrued Expenses	$167.8K	$167.8K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$215.9K	$215.9K
YoY Change
Total Short-Term Liabilities	$860.3K	$860.3K	$978.3K
YoY Change	-12.07%	-12.07%	72.07%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$267.5K
YoY Change	-100.0%	-100.0%
Other Long-Term Liabilities	$588.5K	$588.5K	$8.387M
YoY Change	-92.98%	-92.98%	-47.03%
Total Long-Term Liabilities	$588.5K	$588.5K	$8.655M
YoY Change	-93.2%	-93.2%	-45.34%
TOTAL LIABILITIES
Total Short-Term Liabilities	$860.3K	$860.3K	$978.3K
Total Long-Term Liabilities	$588.5K	$588.5K	$8.655M
Total Liabilities	$1.449M	$1.449M	$9.633M
YoY Change	-84.96%	-84.96%	-41.27%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.370M		-$8.356M
YoY Change	-83.61%		-39.7%
Common Stock	$0.00		$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$53.98M	$53.98M	-$8.356M
YoY Change
Total Liabilities & Shareholders Equity	$55.43M	$55.43M	$216.8M
YoY Change	-74.43%	-74.43%	0.86%

Cashflow Statement

Concept	2023 Q4	2023	2022 Q4
OPERATING ACTIVITIES
Net Income	-$1.024M	$4.386M	$1.383M
YoY Change	-174.07%	-52.81%	-197.03%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$406.9K	-$1.176M	-$645.4K
YoY Change	-36.95%	11.04%	67.74%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$169.1M	$169.1M	$0.00
YoY Change			-100.0%
Cash From Investing Activities	$169.1M	$169.1M	$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	-$169.1M	-$169.1M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-169.1M	-168.8M	404.6K
YoY Change	-41893.48%	-81451.55%	-99.81%
NET CHANGE
Cash From Operating Activities	-406.9K	-1.176M	-645.4K
Cash From Investing Activities	169.1M	169.1M	0.000
Cash From Financing Activities	-169.1M	-168.8M	404.6K
Net Change In Cash	-406.9K	-892.4K	-240.9K
YoY Change	68.96%	4.79%	-113.56%
FREE CASH FLOW
Cash From Operating Activities	-$406.9K	-$1.176M	-$645.4K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent		usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent		usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent		usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable		usd
CY2023Q4	CDAQ	Underwriters Fees Payable UnderwritersFeesPayable		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock		usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock		usd
CY2022	CDAQ	Nonredemption Expense NonredemptionExpense		usd
CY2022	CDAQ	Gain On Settlement Of Deferred Underwriting Fees Attributable To Public Warrants GainOnSettlementOfDeferredUnderwritingFeesAttributableToPublicWarrants		usd
CY2022	CDAQ	Gain On Settlement Of Professional Legal Fees GainOnSettlementOfProfessionalLegalFees		usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
CY2022	CDAQ	Gain On Settlement Of Professional Legal Fees GainOnSettlementOfProfessionalLegalFees		usd
CY2022	CDAQ	Gain On Settlement Of Deferred Underwriting Fees Attributable To Public Warrants GainOnSettlementOfDeferredUnderwritingFeesAttributableToPublicWarrants		usd
CY2022	CDAQ	Nonredemption Expense NonredemptionExpense		usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities		usd
CY2022	us-gaap	Proceeds From Sale Of Other Investments ProceedsFromSaleOfOtherInvestments		usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2022	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt		usd
CY2022	CDAQ	Risk Capital Refund Financing Activities RiskCapitalRefundFinancingActivities		usd
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt		usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
CY2022	us-gaap	Stock Issued1 StockIssued1		usd
CY2022	CDAQ	Deferred Underwriting Fees Waiver DeferredUnderwritingFeesWaiver		usd
CY2022	CDAQ	Allocation Of Polar Capital Investment Payable Proceeds To Equity Instrument AllocationOfPolarCapitalInvestmentPayableProceedsToEquityInstrument		usd
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	true
CY2023	dei	Document Fin Stmt Restatement Recovery Analysis Flag DocumentFinStmtRestatementRecoveryAnalysisFlag	true
CY2023Q2	dei	Entity Public Float EntityPublicFloat	219945253	usd
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	100
CY2023	dei	Auditor Name AuditorName	WithumSmith+Brown, PC
CY2023	dei	Auditor Location AuditorLocation	New York, New York
CY2022	dei	Auditor Firm AuditorFirmId	688
CY2022	dei	Auditor Name AuditorName	Marcum LLP
CY2022	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44046	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	936434	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	35635	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	340965	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	79681	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1277399	usd
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	55347556	usd
CY2022Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	215521445	usd
CY2023Q4	us-gaap	Assets Assets	55427237	usd
CY2022Q4	us-gaap	Assets Assets	216798844	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	476567	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	953511	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	125000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	24821	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	167798	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	860274	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	978332	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	267500	usd
CY2022Q4	CDAQ	Underwriters Fees Payable UnderwritersFeesPayable	7434171	usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	588464	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	952979	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1448738	usd
CY2022Q4	us-gaap	Liabilities Liabilities	9632982	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1369588	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8356114	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1369057	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8355583	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	55427237	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	216798844	usd
CY2023	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1926567	usd
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1173963	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	120000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30000	usd
CY2023	CDAQ	Nonredemption Expense NonredemptionExpense	3444008	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-5490575	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-1203963	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	8914159	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	3113621	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-364515	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7385581	usd
CY2023	CDAQ	Gain On Settlement Of Deferred Underwriting Fees Attributable To Public Warrants GainOnSettlementOfDeferredUnderwritingFeesAttributableToPublicWarrants	246814	usd
CY2023	CDAQ	Gain On Settlement Of Professional Legal Fees GainOnSettlementOfProfessionalLegalFees	351409	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	4386322	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	9295239	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-14534257	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	3116565	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	9295239	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-8355583	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-8355583	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	523000	usd
CY2023	CDAQ	Stock Issued During Period Value Return Of Excess Contribution Capital To Legacy Sponsor StockIssuedDuringPeriodValueReturnOfExcessContributionCapitalToLegacySponsor	-49093	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	3444008	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	409091	usd
CY2023	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	1726802	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	4386322	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1369057	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1369057	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	4386322	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	9295239	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	8914159	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	3113621	usd
CY2023	CDAQ	Gain On Settlement Of Professional Legal Fees GainOnSettlementOfProfessionalLegalFees	351409	usd
CY2023	CDAQ	Gain On Settlement Of Deferred Underwriting Fees Attributable To Public Warrants GainOnSettlementOfDeferredUnderwritingFeesAttributableToPublicWarrants	246814	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-364515	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7385581	usd
CY2023	CDAQ	Nonredemption Expense NonredemptionExpense	3444008	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-305330	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-411833	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	397465	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	85131	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	167798	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1175974	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-706999	usd
CY2023	us-gaap	Proceeds From Sale Of Other Investments ProceedsFromSaleOfOtherInvestments	169088048	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	169088048	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	500000	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	207500	usd
CY2023	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	177500	usd
CY2023	CDAQ	Risk Capital Refund Financing Activities RiskCapitalRefundFinancingActivities	49093	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	24821	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	352081	usd
CY2023	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	35000	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	169088048	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-168804462	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-144581	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-892388	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-851580	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	936434	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1788014	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	44046	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	936434	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	523000	usd
CY2023	CDAQ	Deferred Underwriting Fees Waiver DeferredUnderwritingFeesWaiver	7187357	usd
CY2023	CDAQ	Allocation Of Polar Capital Investment Payable Proceeds To Equity Instrument AllocationOfPolarCapitalInvestmentPayableProceedsToEquityInstrument	409091	usd
CY2023	CDAQ	Accretion Of Class Ordinary Shares To Redemption Value AccretionOfClassOrdinarySharesToRedemptionValue	1726802	usd
CY2022	CDAQ	Accretion Of Class Ordinary Shares To Redemption Value AccretionOfClassOrdinarySharesToRedemptionValue	3116565	usd
CY2021Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10.00
CY2021Q4	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	200000000	usd
CY2023	CDAQ	Purchased An Aggregate PurchasedAnAggregate	20000000	shares
CY2023	CDAQ	Offering Price OfferingPrice	10.00
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	200000000	usd
CY2023	us-gaap	Payments For Underwriting Expense PaymentsForUnderwritingExpense	199999	usd
CY2023	CDAQ	Allocation Of Offering Costs And Founders Shares To Warrant Expense AllocationOfOfferingCostsAndFoundersSharesToWarrantExpense	631124	usd
CY2023	CDAQ	Fair Value In Excess Of Consideration FairValueInExcessOfConsideration	10414655	usd
CY2021Q4	CDAQ	Net Proceeds NetProceeds	200000000	usd
CY2021Q4	CDAQ	Price Per Share PricePerShare	10.00
CY2021Q4	CDAQ	Maturity Days MaturityDays	P185D
CY2021Q4	CDAQ	Private Placement Warrants PrivatePlacementWarrants	165398	shares
CY2021Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	1.50
CY2021Q4	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	248097	usd
CY2023Q4	us-gaap	General Fair Value Hedge Information Minimum R Square Percentage GeneralFairValueHedgeInformationMinimumRSquarePercentage	0.80	pure
CY2023	CDAQ	Percentage Of Outstanding Voting Securities PercentageOfOutstandingVotingSecurities	0.50	pure
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Indefinite Lived Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets	5000001	usd
CY2023	CDAQ	Aggregate Share Percentage AggregateSharePercentage	0.15	pure
CY2023	CDAQ	Trust Account Per Share TrustAccountPerShare	10.65
CY2023	CDAQ	Dissolution Expenses DissolutionExpenses	100000	usd
CY2023	CDAQ	Public Per Shares PublicPerShares	10.00
CY2023	CDAQ	Value Of The Trust Assets ValueOfTheTrustAssets	10.00
CY2023Q4	CDAQ	Operating Bank Account OperatingBankAccount	44046	usd
CY2023Q4	CDAQ	Working Capital WorkingCapital	780593	usd
CY2023Q4	CDAQ	Cash Payments CashPayments	25000	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	125000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84E_eus-gaap--UseOfEstimates_z17WQohpIhcg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zz34eHzeez3a">Use of Estimates</span> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the accompanying financial statements in conformity with GAAP requires Management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the accompanying financial statements and the reported amounts of revenues and expenses during the reporting period. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires Management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the accompanying financial statements, which Management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Cash Cash	44046	usd
CY2022Q4	us-gaap	Cash Cash	936434	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q4	CDAQ	Cash Held In The Trust Account CashHeldInTheTrustAccount	55347556	usd
CY2022Q4	CDAQ	Cash Held In The Trust Account CashHeldInTheTrustAccount	215521445	usd
CY2021Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1240488	shares
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_zoEX0r4c5v53" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zEOgW0OFv1Nd">Concentration of Credit Risk</span> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $<span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zXD0iYaFZ7Jb" title="FDIC insured amount">250,000</span>. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COMPASS DIGITAL ACQUISITION CORP. </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2021Q4	us-gaap	Shares Issued SharesIssued	20000000	shares
CY2021Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	10.00
CY2021Q4	CDAQ	Gross Proceeds GrossProceeds	200000000	usd
CY2021Q4	CDAQ	Incurring Offering Costs IncurringOfferingCosts	11929189	usd
CY2021Q4	us-gaap	Expense Related To Distribution Or Servicing And Underwriting Fees ExpenseRelatedToDistributionOrServicingAndUnderwritingFees	4000000	usd
CY2021Q4	CDAQ	Deferred Underwriting Fees DeferredUnderwritingFees	7000000	usd
CY2021Q4	CDAQ	Other Offering Costs OtherOfferingCosts	929189	usd
CY2021Q4	CDAQ	Shares Issued1 SharesIssued1	20000000	shares
CY2021Q4	CDAQ	Public Offering Price Per Share PublicOfferingPricePerShare	10.00
CY2021Q4	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	248097	usd
CY2023	CDAQ	Sponsor Purchased SponsorPurchased	4666667	shares
CY2023Q4	CDAQ	Price Per Warrant PricePerWarrant	1.50
CY2023	us-gaap	Sale Of Stock Consideration Received Per Transaction SaleOfStockConsiderationReceivedPerTransaction	7000000	usd
CY2023	CDAQ	Aggregate Of Private Placement Warrants AggregateOfPrivatePlacementWarrants	186667	shares
CY2021Q1	us-gaap	Shares Issued SharesIssued	5750000	shares
CY2021Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	25000	usd
CY2021Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	721402	shares
CY2023	CDAQ	Founder Shares Subject To Forfeiture FounderSharesSubjectToForfeiture	750000	shares
CY2023	CDAQ	Companys Issued And Outstanding Percentage CompanysIssuedAndOutstandingPercentage	0.20	pure
CY2023Q4	us-gaap	Share Price SharePrice	12.00
CY2023Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.004
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.50
CY2023	CDAQ	Issued Of Unsecured Promissory Note IssuedOfUnsecuredPromissoryNote	1000000	usd
CY2023Q4	CDAQ	Withdrawn Of Outstanding Working Capital Loans WithdrawnOfOutstandingWorkingCapitalLoans	125000	usd
CY2022Q4	CDAQ	Withdrawn Of Outstanding Working Capital Loans WithdrawnOfOutstandingWorkingCapitalLoans	267500	usd
CY2023Q3	CDAQ	Working Capital Loans WorkingCapitalLoans	1500000	usd
CY2023	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	10000	usd
CY2023	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	40000	usd
CY2022	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	30000	usd
CY2023	CDAQ	Underwriters Shares Additional Units UnderwritersSharesAdditionalUnits	3000000	shares
CY2023	CDAQ	Deferred Underwriting Fees DeferredUnderwritingFees	7434171	usd
CY2023	CDAQ	Gain On Settlement Of Deferred Underwriting Fees GainOnSettlementOfDeferredUnderwritingFees	7187357	usd
CY2023	CDAQ	Gain On Settlement Of Deferred Underwriting Fees Attributable To Public Warrants GainOnSettlementOfDeferredUnderwritingFeesAttributableToPublicWarrants	246814	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	6666667	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	4666667	shares
CY2023	CDAQ	Warrants Expire Date WarrantsExpireDate	P5Y
CY2023	us-gaap	Sale Of Stock Percentage Of Ownership After Transaction SaleOfStockPercentageOfOwnershipAfterTransaction	0.60	pure
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	215521445	usd
CY2023	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	1726802	usd
CY2023	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	7187357	usd
CY2023	CDAQ	Temporary Equity Redemption Of Class A Ordinary Shares TemporaryEquityRedemptionOfClassAOrdinaryShares	-169088048	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	55347556	usd
CY2023Q4	us-gaap	Preferred Units Authorized PreferredUnitsAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Units Authorized PreferredUnitsAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Units Issued PreferredUnitsIssued	0	shares
CY2023Q4	us-gaap	Preferred Units Outstanding PreferredUnitsOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Units Issued PreferredUnitsIssued	0	shares
CY2022Q4	us-gaap	Preferred Units Outstanding PreferredUnitsOutstanding	0	shares
CY2023	CDAQ	Companys Issued And Outstanding Percentage CompanysIssuedAndOutstandingPercentage	0.20	pure

Files In Submission

Name	View Source	Status
0001493152-24-012485-index-headers.html	Edgar Link	pending
0001493152-24-012485-index.html	Edgar Link	pending
0001493152-24-012485.txt	Edgar Link	pending
0001493152-24-012485-xbrl.zip	Edgar Link	pending
cdaq-20231231.xsd	Edgar Link	pending
ex10-19.htm	Edgar Link	pending
ex10-19_001.jpg	Edgar Link	pending
ex10-19_002.jpg	Edgar Link	pending
ex10-19_003.jpg	Edgar Link	pending
ex10-19_004.jpg	Edgar Link	pending
ex10-19_005.jpg	Edgar Link	pending
ex10-19_006.jpg	Edgar Link	pending
ex10-19_007.jpg	Edgar Link	pending
ex10-19_008.jpg	Edgar Link	pending
ex10-19_009.jpg	Edgar Link	pending
ex10-19_010.jpg	Edgar Link	pending
ex10-19_011.jpg	Edgar Link	pending
ex10-19_012.jpg	Edgar Link	pending
ex10-19_013.jpg	Edgar Link	pending
ex10-19_014.jpg	Edgar Link	pending
ex10-20.htm	Edgar Link	pending
ex10-20_001.jpg	Edgar Link	pending
ex10-20_002.jpg	Edgar Link	pending
ex10-20_003.jpg	Edgar Link	pending
ex10-20_004.jpg	Edgar Link	pending
ex10-20_005.jpg	Edgar Link	pending
ex10-20_006.jpg	Edgar Link	pending
ex10-20_007.jpg	Edgar Link	pending
ex10-20_008.jpg	Edgar Link	pending
ex10-20_009.jpg	Edgar Link	pending
ex10-20_010.jpg	Edgar Link	pending
ex10-20_011.jpg	Edgar Link	pending
ex10-20_012.jpg	Edgar Link	pending
ex10-20_013.jpg	Edgar Link	pending
ex10-20_014.jpg	Edgar Link	pending
ex10-20_015.jpg	Edgar Link	pending
ex10-21.htm	Edgar Link	pending
ex10-21_001.jpg	Edgar Link	pending
ex10-21_002.jpg	Edgar Link	pending
ex10-21_003.jpg	Edgar Link	pending
ex10-21_004.jpg	Edgar Link	pending
ex10-21_005.jpg	Edgar Link	pending
ex10-21_006.jpg	Edgar Link	pending
ex10-21_007.jpg	Edgar Link	pending
ex10-21_008.jpg	Edgar Link	pending
ex10-21_009.jpg	Edgar Link	pending
cdaq-20231231_def.xml	Edgar Link	unprocessable
cdaq-20231231_lab.xml	Edgar Link	unprocessable
cdaq-20231231_pre.xml	Edgar Link	unprocessable
ex10-21_010.jpg	Edgar Link	pending
ex10-21_011.jpg	Edgar Link	pending
ex10-21_012.jpg	Edgar Link	pending
ex10-21_013.jpg	Edgar Link	pending
ex10-21_014.jpg	Edgar Link	pending
ex10-21_015.jpg	Edgar Link	pending
ex10-22.htm	Edgar Link	pending
ex10-22_001.jpg	Edgar Link	pending
ex10-22_002.jpg	Edgar Link	pending
ex10-22_003.jpg	Edgar Link	pending
ex10-22_004.jpg	Edgar Link	pending
ex10-22_005.jpg	Edgar Link	pending
ex10-22_006.jpg	Edgar Link	pending
ex10-22_007.jpg	Edgar Link	pending
ex10-22_008.jpg	Edgar Link	pending
ex10-22_009.jpg	Edgar Link	pending
ex10-22_010.jpg	Edgar Link	pending
ex10-22_011.jpg	Edgar Link	pending
ex10-22_012.jpg	Edgar Link	pending
ex10-22_013.jpg	Edgar Link	pending
ex10-22_014.jpg	Edgar Link	pending
ex10-22_015.jpg	Edgar Link	pending
ex10-23.htm	Edgar Link	pending
ex10-23_001.jpg	Edgar Link	pending
ex10-23_002.jpg	Edgar Link	pending
ex10-23_003.jpg	Edgar Link	pending
ex10-23_004.jpg	Edgar Link	pending
ex10-23_005.jpg	Edgar Link	pending
ex10-23_006.jpg	Edgar Link	pending
ex10-23_007.jpg	Edgar Link	pending
ex10-23_008.jpg	Edgar Link	pending
ex10-23_009.jpg	Edgar Link	pending
ex10-23_010.jpg	Edgar Link	pending
ex10-23_011.jpg	Edgar Link	pending
ex10-23_012.jpg	Edgar Link	pending
ex10-23_013.jpg	Edgar Link	pending
ex10-23_014.jpg	Edgar Link	pending
ex10-23_015.jpg	Edgar Link	pending
ex10-24.htm	Edgar Link	pending
ex10-24_001.jpg	Edgar Link	pending
ex10-24_002.jpg	Edgar Link	pending
ex10-24_003.jpg	Edgar Link	pending
ex10-24_004.jpg	Edgar Link	pending
ex10-24_005.jpg	Edgar Link	pending
ex10-24_006.jpg	Edgar Link	pending
ex10-24_007.jpg	Edgar Link	pending
ex10-24_008.jpg	Edgar Link	pending
ex10-24_009.jpg	Edgar Link	pending
ex10-24_010.jpg	Edgar Link	pending
ex10-24_011.jpg	Edgar Link	pending
ex10-24_012.jpg	Edgar Link	pending
ex10-24_013.jpg	Edgar Link	pending
ex10-24_014.jpg	Edgar Link	pending
ex10-24_015.jpg	Edgar Link	pending
ex10-25.htm	Edgar Link	pending
ex10-25_001.jpg	Edgar Link	pending
ex10-25_002.jpg	Edgar Link	pending
ex10-25_003.jpg	Edgar Link	pending
ex10-25_004.jpg	Edgar Link	pending
ex10-25_005.jpg	Edgar Link	pending
ex10-25_006.jpg	Edgar Link	pending
ex10-25_007.jpg	Edgar Link	pending
ex10-25_008.jpg	Edgar Link	pending
ex10-25_009.jpg	Edgar Link	pending
ex10-25_010.jpg	Edgar Link	pending
ex10-25_011.jpg	Edgar Link	pending
ex10-25_012.jpg	Edgar Link	pending
ex10-25_013.jpg	Edgar Link	pending
ex10-25_014.jpg	Edgar Link	pending
ex10-25_015.jpg	Edgar Link	pending
ex10-26.htm	Edgar Link	pending
ex10-26_001.jpg	Edgar Link	pending
ex10-26_002.jpg	Edgar Link	pending
ex10-26_003.jpg	Edgar Link	pending
ex10-26_004.jpg	Edgar Link	pending
ex10-26_005.jpg	Edgar Link	pending
ex10-26_006.jpg	Edgar Link	pending
ex10-26_007.jpg	Edgar Link	pending
ex10-26_008.jpg	Edgar Link	pending
ex10-26_009.jpg	Edgar Link	pending
ex10-26_010.jpg	Edgar Link	pending
ex10-26_011.jpg	Edgar Link	pending
ex10-28.htm	Edgar Link	pending
ex14.htm	Edgar Link	pending
ex14_001.jpg	Edgar Link	pending
ex14_002.jpg	Edgar Link	pending
ex14_003.jpg	Edgar Link	pending
ex14_004.jpg	Edgar Link	pending
ex14_005.jpg	Edgar Link	pending
ex14_006.jpg	Edgar Link	pending
ex19.htm	Edgar Link	pending
ex19_001.jpg	Edgar Link	pending
ex19_002.jpg	Edgar Link	pending
ex19_003.jpg	Edgar Link	pending
ex19_004.jpg	Edgar Link	pending
ex19_005.jpg	Edgar Link	pending
ex19_006.jpg	Edgar Link	pending
ex19_007.jpg	Edgar Link	pending
ex19_008.jpg	Edgar Link	pending
ex19_009.jpg	Edgar Link	pending
ex19_010.jpg	Edgar Link	pending
ex19_011.jpg	Edgar Link	pending
ex19_012.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-5.htm	Edgar Link	pending
ex97.htm	Edgar Link	pending
ex99-1.htm	Edgar Link	pending
ex99-1_001.jpg	Edgar Link	pending
ex99-1_002.jpg	Edgar Link	pending
ex99-1_003.jpg	Edgar Link	pending
ex99-1_004.jpg	Edgar Link	pending
ex99-1_005.jpg	Edgar Link	pending
ex99-1_006.jpg	Edgar Link	pending
ex99-2.htm	Edgar Link	pending
ex99-2_001.jpg	Edgar Link	pending
ex99-2_002.jpg	Edgar Link	pending
ex99-2_003.jpg	Edgar Link	pending
ex99-3.htm	Edgar Link	pending
ex99-3_001.jpg	Edgar Link	pending
ex99-3_002.jpg	Edgar Link	pending
ex99-3_003.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
form10-k_htm.xml	Edgar Link	completed
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cdaq-20231231_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CDAQF
Compass Digital Acquisition Corp. Stock $cdaqf

2023 Q4 Form 10-K Financial Statement

#000149315224012485 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDAQF Compass Digital Acquisition Corp. Stock $cdaqf

2023 Q4 Form 10-K Financial Statement

#000149315224012485 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDAQF
Compass Digital Acquisition Corp. Stock $cdaqf